低剂量地西他滨与支持治疗对骨髓增生异常综合征低危患者预后的影响

目的 分析探讨低剂量地西他滨与支持治疗对骨髓增生异常综合征低危患者预后的影响。方法 选取2016年10月-2018年10月于西安市中心医院收治的110例骨髓增生异常综合征患者，根据治疗方案的不同将所有患者分为对照组和观察组，每组各55例。对照组患者均给予支持治疗，而观察组患者则在对照组基础上给予低剂量地西他滨进行治疗。第1~5天为1个疗程，每个疗程至少间隔3周，治疗至少2个疗程。比较两组患者的临床疗效和不良反应发生情况。结果 治疗后，观察组患者的总有效率为67.27%，显著优于对照组患者的34.55%（P<0.05）。治疗后，观察组患者中出现3级以上感染和因不良反应死亡的不良情况发生率分别为32.73%和3.64%，均显著低于对照组患者的60.00%和29.09%（P<0.05）。结论 对骨髓增生异常综合征低危患者采用低剂量地西他滨治疗能够有效改善患者的临床预后，在降低其不良反应发生率的同时大大提升了治疗效果，值得在临床上加以推广运用。

Effect of low dose dietabine and supportive therapy on prognosis of low risk patients with myelodysplastic syndrome

Objective To investigate the effect of low dose dietabine and supportive therapy on prognosis of low risk patients with myelodysplastic syndrome. Methods Patients (110 cases) with myelodysplastic syndrome in Xi''an Central Hospital from October 2016 to October 2018 were divided into control and observation groups according to different treatment, and each group had 55 cases. Patients in the control group were given support treatment, while the observation group were given low dose dietabine on the basis of control group. The first to the fifth day is a course of treatment, each course is at least 3 weeks apart, and patients in two groups were treated for 2 courses. The clinical efficacy and adverse reactions in two groups were compared. Results After treatment, the total effective rate of the observation group was 67.27%, which was higher than 34.55% of the control group (P<0.05). After treatment, the incidence of infection above grade 3 and the death due to adverse reactions in the observation group were 32.73% and 3.64%, respectively, which were significantly lower than those in the 60.00% and 29.09% in the control group (P<0.05). Conclusion The treatment of low risk patients with myelodysplastic syndrome with low dose of dicitabine can effectively improve the clinical prognosis, reduce the incidence of adverse reactions and greatly improve the efficacy of the treatment, it is worth to be popularized in clinical use.